Genmab (GMAB)
(Delayed Data from NSDQ)
$30.62 USD
-0.21 (-0.68%)
Updated Mar 27, 2024 03:59 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 1 - 20 ( 107 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
2023 Financials Reported; Numerous Catalysts Expected in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 2023 Sales Reported; Genmab Appeal Denied; Modulating PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Numerous Datasets Presented at ASH Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Positive Follicular Lymphoma Regulatory Feedback; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for GMAB 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
sBLA Submitted For RYBREVANT + Chemo in EGFR+ NSCLC Post-Tagrisso; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Multiple Datasets Expected at ASH; 3Q23 Financials; Modulating PT to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
TIVDAK and RYBREVANT Both Shine at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
3Q23 DARZALEX Sales Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Obtains Conditional European Marketing Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
TIVDAK InnovaTV-301 Trial Meets Overall Survival Endpoint; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
TALVEY Granted Accelerated Approval by FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 2Q23 Sales Announced; Guidance Raised; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Relapsed/Refractory Follicular Lymphoma Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Added to National Clinical Practice Guidelines; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Clinical Program and Competitive Landscape Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
NICE Recommends DARZALEX in 2L Multiple Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Receives Accelerated Approval; Raising PT to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q23 Financials; Multiple Datasets at ASCO and EHA; Raising PT to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R